Screening for scleroderma antibodies is used in the evaluation of patients with signs and symptoms of scleroderma and other connective tissue diseases in whom the test for antinuclear antibodies is positive.
Scleroderma antibodies (Scl-70) are found in patients with progressive systemic sclerosis (scleroderma) and in patients with CREST syndrome. CREST syndrome (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia) is characterized by calcification, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia. The positive results of this test are considered highly specific for the diagnosis of scleroderma because Scl-70 antibodies are only rarely found in other diseases such as mixed connective tissue disease, rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus.
Important Note
Laboratory test results are the most important parameter for the diagnosis and monitoring of all pathological conditions. 70%-80% of diagnostic decisions are based on laboratory tests. The correct interpretation of laboratory results allows a doctor to distinguish "healthy" from "diseased".
Laboratory test results should not be interpreted from the numerical result of a single analysis. Test results should be interpreted in relation to each individual case and family history, clinical findings, and the results of other laboratory tests and information. Your personal physician should explain the importance of your test results.
At Diagnostiki Athinon we answer any questions you may have about the test you perform in our laboratory and we contact your doctor to get the best possible medical care.
